We design recognition.
The healthcare and diagnostics industry relies on recognition. Every day, thousands of tests and procedures that depend on sensitive and specific recognition of chemical and biological substances are carried out. The results provide critical information, including what treatment people receive, and inevitably what quality of life they will live.
MIP Discovery designs high value, synthetic recognition reagents to support a healthier society, with a particular focus in two key areas: drugs of abuse testing and cell and gene therapy.
MIP Discovery is designing high value, synthetic recognition reagents to support a healthier, happier society, with a particular focus in two key areas; drugs of abuse testing and cell and gene therapy.
Drugs of Abuse Testing
nanoMIPs are enabling the next generation of rapid, in-field drugs of abuse tests.
Cell and Gene Therapy Solutions
nanoMIPs are supporting the industrialisation of cell and gene therapy processes and real time monitoring.
Why synthetic affinity reagents?
Recognition by design
Our ‘recognition by design’ ethos will enable our partners to create best-in-class diagnostic tools by placing rationally designed affinity reagents at the core of their platforms and technologies.
Rational design and chemical manufacturing processes means our customers always get reproducible and scalable affinity reagents. We use our experience and expertise to eliminate risk and ensure consistency.
nanoMIPs are ethically produced and animal component free. Their chemical nature allows for use in extreme environments and harsh conditions without impacting performance.
Trusted by Industry Innovators
Professor Tony Turner
Pioneer of home blood glucose monitoring
“The weakness of biological materials is their instability when incorporated into bioelectronic devices like biosensors. I have long been interested in biomimetic alternatives to biomolecules to overcome this. This eventually led us to create the first MIP-based electrochemical sensor.”
Professor Sharath Sriram
Named one of Australia’s most innovative engineers
“My team and I have one core objective: to make science fiction reality. To me, molecularly imprinted polymers (MIPs) are a gamechanger to creating practical biosensors suitable for clinical and retail markets.”